Ampligen®.
Hemispherx has in excess of 100 patents comprising its core intellectual property estate covering various forms of double stranded (ds) RNA and their fields of therapeutic application, a fully commercialized product (Alferon N) and a GMP certified manufacturing facilities for its novel pharma products in New Brunswick, New Jersey. http://www.hemispherx.net/content/rnd/drug_candidates.htm
One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia, PA 19103 |
| Phone: | (215) 988-0080 |
| Fax: | (215) 988-1739 |
The Long Wait Of Hemispherx's Ampligen
http://www.tradingmarkets.com/.site/news/TOP%20STORY/2188007/
Ampligen (Hemispherx) http://www.ei-resource.org/treatment-%11-medications/antiviral/ampligen-(hemispherx)/
FDA delays Hemispherx drug vote
Philadelphia Business Journal - by John George February 2009
PHILADELPHIA, Oct. 23, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) noted today that a member of its Scientific Advisory Board, Prof. Luc Montagnier, a winner of the 2008 Nobel Prize in Physiology and Medicine, confirms the importance of adjuvants in a current article in the Wall Street Journal (Oct. 21, 2008, p.A19). http://www.globenewswire.com/newsroom/news.html?ref=rss&d=152779
Hemispherx Biopharma (HEB): One Step Closer http://smallcaps.us/blog/?p=21
| Dear patients:
We were very pleased that our four years of research trials on Ampligen for Chronic Fatigue Syndrome turned out to be successful. The press release below summarizes the results--that Ampligen was more effective than placebo for improving the exercise capacity among people with severe CFS. |
http://www.drpodell.org/ampligen.shtml
Hemispherx Biopharma, Inc. to Discuss New Chronic Fatigue Syndrome Clinical Data and Year-End 2008 Results On March 19, 2009
http://finance.yahoo.com/news/Hemispherx-Biopharma-Inc-to-pz-14666481.html
Japanese Government Accelerates Hemispherx Biopharma's Ampligen(r) Research Programs for Influenza Protection
http://finance.yahoo.com/news/Japanese-Government-pz-15041028.html
Interview with Dr. William Carter April 28,2009
Slides of Ampligen® Trial Results Used in Presentation at IACFS/ME Conference March 19, 2009
http://www.prohealth.com/library/showarticle.cfm?LIBID=14408
A decision was originally expected by February 25, 2009, for the Company's submission of its Ampligen(r) NDA, which is designated as an Orphan Drug for the treatment of Chronic Fatigue Syndrome, which has no FDA approved treatments on the market. Ampligen(r) is also authorized for Emergency (compassionate) Cost Recovery Sales Authorization by the FDA and has a "promising" designation by the Agency on Health Research Quality (AHRQ): "Ampligen(r), an investigational drug that is not approved by the FDA, given intravenously to severely debilitated patients, yielded the most promising results." The extended user fee goal date is now May 25th, 2009.
http://www.marketwatch.com/news/story/fda-extends-hemispherxs-nda-review/story.aspx?guid=%7BC2018758-49E2-491D-B842-9C2DCA8AE6F5%7D
Chronic Fatigue Syndrome Treatment - Will Ampligen Finally Be Approved?
http://chronicfatigue.about.com/b/2009/01/06/chronic-fatigue-syndrome-treatment-will-ampligen-finally-be-approved.htm
http://www.cdc.gov/CFS/
CDC - Chronic Fatigue Syndrome (CFS).
http://www.hhs.gov/advcomcfs/
HHS - Chronic Fatigue Syndrome Advisory Committee (CFSAC)
Department of Health and Human Services Center for Disease Control and Prevention Public Service Announcments in regards to Chronic Fatigue Syndrome
(30 second and 60 second radio ad, 30 second television ad, and message from Dr. Gerberding)
http://www.cdc.gov/cfs/psas.htm
PIPELINE.
